5-aminolevulinic acid (5-ALA) / Fox Chase Cancer Center - LARVOL DELTA

An In Vitro Investigation of 5-Aminolevulinic Acid and Acridine Orange as Sensitizers in Radiodynamic Therapy for Prostate and Breast Cancer. (PubMed, Biomed Phys Eng Express) - "Both 5-ALA and AO enhanced the cytotoxic effects of radiation, but 5-ALA demonstrated superior biocompatibility and more consistent radiosensitization across both cell lines. Notably, the effectiveness of both sensitizers increased with higher photon energy, reinforcing the importance of beam energy in RDT design. These results underscore the advantages of 5-ALA over AO and highlight the need to optimize both sensitizer selection and radiation energy in clinical applications."

Journal • Preclinical • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Phase I Study in Advanced Malignancies With 5-ALA (clinicaltrials.gov) - P1 | N=130 | Suspended | Sponsor: Fox Chase Cancer Center | Recruiting ➔ Suspended

Trial suspension • Oncology • Solid Tumor

Maximizing Tumor Growth Delay: The Impact of Carbamide Peroxide Catalysis in Megavoltage Radiodynamic Therapy with 5-Aminolevulinic Acid (ASTRO 2025) - "The catalytic effect of photon irradiation, PpIX, and carbamide peroxide was observed in-vivo 5-ALA RDT. The enhancement results suggest that the additional ROS produced by PRX prolongs the tumor growth delay in 5-aminolevulinic acid radiodynamic therapy."

Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Radiodynamic Therapy as a Potential Strategy for Metastatic Control in Small-cell Lung Cancer: A Preclinical Study. (PubMed, Biomed Phys Eng Express) - "Kaplan-Meier survival data analysis demonstrated a significant survival benefit in RDT treated mice compared to RT and control groups, with statistical analysis confirming a significant extension of lifespan in both RDT cohorts (p < 0.004). These findings show that RDT reduces the rate of metastatic progression and improves survival outcomes in a premetastatic SCLC model, supporting its potential as a systemic therapeutic strategy for metastases."

Journal • Preclinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Investigating Tumor Response and Efficacy of 5-Aminolevulinic Acid-Mediated Radiodynamic Therapy: Utilizing Photon Irradiation, Activation of Photosensitizer and Catalytic Effects (ASTRO 2024) - "5-ALA-mediated RDT significantly improves the therapeutic ratio compared to conventional radiation treatment. Nevertheless, the ratio can be improved further by increasing the photon energy and introducing PRX."

Clinical • Oncology

Tumor Regression with 5-Aminolevulinic Acid (5-ALA)-Mediated Radiodynamic Therapy (RDT) Using Different Megavoltage Energies. (PubMed, Int J Radiat Oncol Biol Phys) - "Radiodynamic therapy using 5-ALA administration and 45MV photon beam irradiation resulted in the most significant tumor growth control. A photon energy dependency was observed in radiodynamic therapy. 45MV photon beams showed greater in activating PpIX, improving the synergistic effects of radiation dose and activated photosensitizer than the other energies. The preliminary results provide a foundation for new innovative treatment strategies that have the potential to improve cancer treatment."

Journal • Oncology • Solid Tumor

Investigation of Hydrogen Peroxide for 45MV 5-Aminolevulinic Acid-Mediated Radiodynamic Therapy (ASTRO 2023) - "45MV 5-ALA-mediated RDT with hydrogen peroxide resulted in the most significant tumor growth delay compared to the other groups. The catalytic effect of PpIX and hydrogen peroxide was observed in-vivo . These preliminary results demonstrate an effective cancer treatment modality."

Oncology

Investigation of Hydrogen Peroxide for 45MV 5-Aminolevulinic Acid-Mediated Radiodynamic Therapy. (PubMed, Int J Radiat Oncol Biol Phys) - "A total of 45MV 5-ALA-mediated RDT with hydrogen peroxide resulted in the most significant tumor growth delay compared to the other groups. The catalytic effect of PpIX and hydrogen peroxide was observed in-vivo. These preliminary results demonstrate an effective cancer treatment modality."

Journal • Oncology

Tumor Regression with 5-Aminolevulinic Acid (5-ALA)-Mediated Radiodynamic Therapy (RDT) Using Different Megavoltage Energies (ASTRO 2023) - "Radiodynamic therapy using 5-ALA administration and 45MV photon beam irradiation resulted in the most significant tumor growth control. A photon energy dependency was observed in radiodynamic therapy. 45MV photon beams showed greater in activating PpIX, improving the synergistic effects of radiation dose and activated photosensitizer than the other energies."

Oncology • Solid Tumor

Advancing Bladder Cancer Surveillance: The Impact of Flexible Blue Light Cystoscopy from the Nordic Registry - Karsten Zieger (Urotoday) - "Zach Klaassen is joined by...to talk about the results of an analysis from the Nordic registry evaluating the role of flexible blue light cystoscopy in the surveillance of non-muscle invasive bladder cancer....The discussion moves on to the objectives and design of the study, where the technology was particularly focused on high-risk patients under surveillance."

Video

Evaluating Therapeutic Effects of In Vivo 15MV Radiodynamic Therapy (RDT) with 5-Aminolevulinic Acid (5-ALA) Using 1.5T MRI and [18F]FDG PET/CT (ASTRO 2022) - "Assessment of radiodynamic therapy combined with 5-ALA administration and 15 MV high-energy radiation treatment showed improved treatment outcomes compared to the control, RT only, and 5-ALA only groups. Tumor growth delay and tumor activity suppression were significantly improved. Moreover, a synergistic effect of 5-ALA and 15 MV photon beams was observed."

FDG PET • Preclinical • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor

Therapeutic effects ofin-vivoradiodynamic therapy (RDT) for lung cancer treatment: a combination of 15MV photons and 5-aminolevulinic acid (5-ALA). (PubMed, Biomed Phys Eng Express) - "RDT with 15MV photons and 5-ALA resulted in greater tumor control compared to the control and other treatment groups. A significant synergistic effect was also observed with RDT. These preliminary results demonstrate an effective cancer treatment modality."

Journal • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor

5-aminolevulinic Acid In Advanced Malignancies (clinicaltrials.gov) - P1; N=130; Recruiting; Sponsor: Fox Chase Cancer Center; Not yet recruiting ➔ Recruiting; Initiation date: Jul 2021 ➔ Jul 2020

Enrollment open • Trial initiation date • Oncology • Solid Tumor

5-AMINOLEVULINIC ACID FLUORESCENCE GUIDED SURGERY IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: A PILOT TRIAL (AHNS 2022) - No abstract available.

5-aminolevulinic Acid In Advanced Malignancies (clinicaltrials.gov) - P1; N=130; Not yet recruiting; Sponsor: Fox Chase Cancer Center; Initiation date: Jul 2020 ➔ Jul 2021

Trial initiation date • Oncology • Solid Tumor

Phase I Study in Advanced Malignancies (clinicaltrials.gov) - P1; N=130; Recruiting; Sponsor: Fox Chase Cancer Center; Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

CSIR seeks regulatory nod for clinical trials using combination of antivirals and HDTs against COVID-19 (ExpressPharma) - "The Council of Scientific & Industrial Research (CSIR), in collaboration with Laxai Life Sciences Hyderabad, has sought regulatory approval to undertake four-arm randomised controlled phase III clinical trial. The design principle of the study is...determine safety and efficacy of the three combination drugs (Favipiravir+Colchicine, Umifenovir+Colchicine and Nafamostat+5-ALA) and a control arm with the standard of care in COVID-19 patients. The clinical trial named MUCOVIN, to be carried out in the partnership with Medanta Medicity..."

Cytokine storm • New P3 trial • Infectious Disease • Novel Coronavirus Disease

5-aminolevulinic Acid In Advanced Malignancies (clinicaltrials.gov) - P1; N=130; Not yet recruiting; Sponsor: Fox Chase Cancer Center

New P1 trial • Oncology • Solid Tumor

Phase I Study With 5-aminolevulinic Acid In Advanced Malignancies (clinicaltrials.gov) - P1; N=130; Not yet recruiting; Sponsor: Fox Chase Cancer Center

New P1 trial • Oncology • Solid Tumor